HealthBeacon's Injection Care Management System added to Evernorth's Digital Health Formulary
Dublin, 15 September 2022: HealthBeacon plc ("HealthBeacon" or the "Company"), the leading digital therapeutics company for managing injectable medications for patients in the home, is pleased to announce its evidence-based Injection Care Management System ("ICMS") has been included on Evernorth's Digital Health Formulary, which connects employers, insurers, and patients with innovative, affordable, and evidence-based care that meet their broader health care needs. The ICMS will help improve care and adherence therapy for thousands of patients in the U.S. who depend on injectable medications to manage inflammatory conditions.
Approximately 50% of patients fail to adhere to their therapy when long-term medication is prescribed (WHO). Adherence and persistence are key factors associated with the effectiveness of all pharmacological therapies as well as being particularly critical for medications prescribed for chronic conditions.
Jim Joyce, CEO, and co-founder of HealthBeacon, said: "Inclusion on the Evernorth Digital Health Formulary is a significant and exciting milestone for HealthBeacon, unlocking greater access to our injection care management system for the millions of patients in the U.S. that self-administer subcutaneous injections at home. Collaborating with Evernorth not only supports HealthBeacon's ambition to make our product globally accessible, but it is also an important validation of the clinical effectiveness of our technology. This development is further evidence that our ambition to be a global leader in adherence devices is being realised."
HealthBeacon's ICMS has improved medication adherence for patients on injection therapy by up to 26%. It includes a Federal Drug Administration (FDA)-cleared Smart Sharps Bin device technology, Companion Medication Adherence mobile app, as well as a sustainable mail-back waste management solution.
Evernorth's Digital Health Formulary is an industry-first platform of credible health apps created in 2019 to make it easier for patients, employers, and health plans to navigate the crowded digital health landscape. Solutions on the Evernorth Digital Health Formulary are reviewed by physicians, pharmacists, and user experience experts, and are only added if they meet quality standards for clinical effectiveness, security and privacy requirements, value and affordability, and user experience.
| Enquiries: |
|
| HealthBeacon: Laurence Flavin
|
Investor.Relations@HealthBeacon.com
|
| Goodbody (Euronext Listing Sponsor and Broker): David Kearney |
+353 (1) 667 0420 |
| Stephen Kane |
|
|
Drury (Public Relations): |
|
| Cathal Barry |
+353 (0) 87 227 9281 |
| Paul Clifford |
+353 (0) 87 327 2161 |
About HealthBeacon
Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company that develops smart tools for managing medications for patients in the home. The HealthBeacon Injection Care Management System tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools, and artificial intelligence (AI) driven data analytics. Peer reviewed evidence supports a 19% improvement in therapy persistence by patients and up to 26% improvement in adherence to therapy, which improves clinical outcomes and significantly improves efficiency in health systems. The Company has expanded its offering to growth management with the launch of its integrated Smart Scale and oral adherence with the launch of HB Smart Pillstm which integrate with its existing technology. The Company operates across Europe, North America and the United Kingdom and employs more than 70 people and has obtained more than 30 design and utility patents. The Company's mission is to become the world's leading digital therapeutics platform for patients managing medications in the home.
Ends
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.